Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):        

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):        

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. 

---

On May 19 and 20, 2021, the Registrant issued press releases and a presentation, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3 and are incorporated herein by reference.

Exhibits
99.1		Press release dated May 19, 2021
99.2		Press release dated May 20, 2021
99.3		Presentation dated May 20, 2021

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Valneva SE
		(Registrant)
Date: May 21, 2021		/s/ Thomas Lingelbach
		Thomas Lingelbach
		Chief Executive Officer and President

Exhibit 99.1

Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK

Saint-Herblain (France), May 19, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced it will participate in a UK government-funded clinical trial looking at different COVID-19 ‘booster’ vaccines that launches today.     

The Cov-Boost trial, led by University Hospital Southampton NHS Foundation Trust, will look at seven different COVID-19 vaccines, including Valneva’s inactivated vaccine VLA2001, as potential boosters. It will be the first trial in the world to provide vital data on how effective a booster of each vaccine is in protecting individuals from the virus.

The vaccines will be given at least three months after a second dose as part of the ongoing vaccination programme. One booster will be provided to each volunteer and could be a different brand to the one they were originally vaccinated with. The trial will also include a control group.

Initial results from the trial, expected in September, will help inform decisions by the UK Joint Committee on Vaccination and Immunisation (JCVI) on any potential booster programme from autumn this year, ensuring the UK’s most vulnerable people are given the strongest possible protection over the winter period.

Thomas Lingelbach, Chief Executive Officer of Valneva, commented, “We are pleased to be involved in this new Cov-Boost trial. Valneva has the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe and we believe our VLA2001 vaccine has an important role to play in the ongoing pandemic, including as a booster. We remain fully committed to completing development and bringing our inactivated vaccine solution to the market.”

In parallel to the Cov-Boost trial, Valneva will continue working on its pivotal Phase 3 clinical trial “Cov-Compare”, (VLA2001-301) which the Company launched in April 2021¹. This trial compares Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria². Recruitment for the trial, conducted in the U.K. and supported by the National Institute for Health Research (NIHR), is ongoing (https://www.ukcovid19study.com/). Subject to successful Phase 3 data, Valneva aims to make regulatory submissions for initial approval in the autumn of 2021.

About VLA2001
VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO^®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B^® vaccine. The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes inactivation with BPL to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees Celsius).

About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to address these diseases. We have leveraged our expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine Director Investor Relations & Corporate Communications M +33 (0)6 4516 7099 investors@valneva.com

Dan Sharp Government & Public Affairs Manager T +44-(0)7436-244309 communications@valneva.com

Valneva Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates and estimates for future performance. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

---

1 Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
2 Approved by MHRA under reg. 174 and by the European Commission as conditional approval

Exhibit 99.2

Valneva Reports Q1 2021 Financial Results and Business Update

     Excellent progress on clinical programs in the first quarter of 2021 for:

• VLA15, currently the only clinical stage vaccine candidate against Lyme disease
  • Initiation of additional Phase 2 trial to accelerate pediatric development
• VLA2001, currently the only inactivated, adjuvanted vaccine candidate for COVID-19 in clinical trials in Europe:
  • Initiation of pivotal Phase 3 clinical trial
  • Participation in the world’s first COVID-19 vaccine booster trial in the UK
  • Publication of Phase 1/2 results
• VLA1553, currently the only Phase 3 chikungunya vaccine program worldwide
  • Recruitment completion for pivotal Phase 3 trial

• Successful Nasdaq listing (Q2 event); $107.6 million of gross proceeds raised in a US initial public offering and a concurrent private placement in Europe
• Cash and cash equivalents of €235.9 million at March 31, 2021
  • Q1 2021 cash and cash equivalents do not include proceeds of $107.6 million from the Company’s recent Global Offering
• Total revenue of €23.2 million in the first quarter of 2021 compared to €35.2 million in the first quarter of 2020
  • Product sales of €16.1 million in the first quarter of 2021 (€32.7 million in the first quarter of 2020), affected by the COVID-19 pandemic impact on the travel industry
  • €7.1 million of Other Revenues (revenues from collaborations, licensing and services) in the first quarter of 2021 (€2.5 million in the first quarter of 2020)
• EBITDA¹ loss of €28.3 million in the first quarter of 2021 reflecting increased R&D investment in clinical stage programs, and lower sales (compared to EBITDA profit of €2.4 million in Q1 2020)
  • R&D investment increased to €27.7 million in the first quarter of 2021 compared to €13.3 million in the first quarter of 2020
    

FY 2021 financial guidance updated
Updated guidance, excluding VLA2001 related activities (including revenue, costs of goods sold, R&D investments), for full-year 2021:

• Total revenues, excluding VLA2001, of €80 million to €105 million
  • Range modified noting that, despite initial signs of recovery in travel vaccine sales being seen, the 2021 outlook remains soft
• R&D expenses, excluding VLA2001, of €65 million to €75 million
  

Thomas Lingelbach, Valneva’s Chief Executive Officer, commented, “Valneva continues to achieve significant R&D milestones thanks to the huge efforts of our team and our partners. Our recent successful Nasdaq listing marks a significant strategic step for Valneva as we look forward. I would like to take this opportunity to thank our existing and new shareholders, partners and employees for their support and contribution to our journey. We are now in a strong position to continue to execute our key programs and continue to build shareholder value.”

Financial Information
(unaudited results, consolidated under IFRS)

€ in million	3 months ending March 31
	2021	2020
Total revenues	23.2	35.2
Product sales	16.1	32.7
Net profit/(loss)	(27.7)	(1.2)
EBITDA	(28.3)	2.4
Cash	235.9	80.8

Saint Herblain (France), May 20, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, reported today its first quarter financial results ending March 31, 2021. The condensed consolidated interim financial results are available on the Company’s website www.valneva.com.

Valneva will provide a live webcast of its first quarter financial results conference call beginning at 3 p.m. CET today. This webcast will also be available on the Company’s website. Please refer to this link: https://edge.media-server.com/mmc/p/bhohhzn6

Commercial Vaccines

JAPANESE ENCEPHALITIS VACCINE (IXIARO^®/JESPECT^®)
IXIARO^® is the only Japanese encephalitis vaccine licensed and available in the United States, Canada and Europe.

Sales of IXIARO^® were €13.3 million in the first quarter of 2021 compared to €22.9 million in the first quarter of 2020. First quarter 2021 sales were affected by the COVID-19 pandemic’s impact on the travel industry.

CHOLERA / ETEC²-DIARRHEA VACCINE (DUKORAL^®)

DUKORAL^® is an oral vaccine for the prevention of diarrhea caused by Vibrio cholerae and/or heat-labile toxin producing ETEC, the leading cause of travelers’ diarrhea. DUKORAL^® is authorized for use in the European Union and Australia to protect against cholera and in Canada, Switzerland, New Zealand and Thailand to protect against cholera and ETEC⁸.

DUKORAL^® recorded sales of €0.1 million in the first quarter of 2021 compared to €9.7 million in the first quarter of 2020. First quarter 2021 sales were significantly affected by the COVID-19 pandemic impact on the travel industry.
Clinical Stage Vaccine Candidates

LYME DISEASE VACCINE CANDIDATE – VLA15
Acceleration of pediatric development

Valneva is developing VLA15, a vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common strains found in the United States and Europe. VLA15 is the only vaccine undergoing clinical trials against Lyme disease.

Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15³. Valneva has reported positive initial results for two Phase 2 clinical trials of VLA15 in over 800 healthy adults.

As part of the collaboration with Pfizer, Valneva announced in December 2020⁴ that it had accelerated VLA15’s pediatric development with the initiation of an additional Phase 2 clinical trial, VLA15-221. The dosing of the first trial participant in March 2021⁵ triggered a milestone payment from Pfizer of $10 million that was received in the second quarter of 2021. Initial pediatric data are expected by mid-2022.

SARS-CoV-2 VACCINE CANDIDATE – VLA2001

Pivotal Phase 3 clinical trial initiated

VLA2001 is a vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.

In April 2021, Valneva reported initial data from the Phase 1/2 clinical trial in which VLA2001 showed high immunogenicity and was generally well tolerated, with no safety concerns identified.

The Company initiated a pivotal Phase 3 clinical trial in April 2021 and aims to make initial regulatory licensure submissions in the autumn of 2021. In parallel, Valneva has developed viral seed banks, including South African and Kent, to be in a position to manufacture variant-based vaccines.

Valneva also announced yesterday that it is participating in a UK government-funded clinical trial looking at different COVID-19 ‘booster’ vaccines. The Cov-Boost trial, led by University Hospital Southampton NHS Foundation Trust, will look at seven different COVID-19 vaccines, including Valneva’s inactivated vaccine VLA2001, as potential boosters. It will be the first trial in the world to provide vital data on how effective a booster of each vaccine is in protecting individuals from the virus.

The vaccines will be given at least three months after a second dose as part of the ongoing vaccination programme. One booster will be provided to each volunteer and could be a different brand to the one they were originally vaccinated with. The trial will also include a control group.

Initial results from the trial, expected in September, will help inform decisions by the UK Joint Committee on Vaccination and Immunisation (JCVI) on any potential booster programme from autumn this year, ensuring the UK’s most vulnerable people are given the strongest possible protection over the winter period.

Although vaccines against SARS-CoV-2 have already been approved, given the potential advantages often associated with inactivated whole virus vaccines, Valneva believes its vaccine will play a role in the overall portfolio of SARS-CoV-2 vaccines that will address the global need during the pandemic and in the future.

In September 2020, Valneva announced a collaboration with the UK Government, which has the option to purchase up to 190 million doses through 2025⁶. So far, the UK Government has ordered 100 million doses for supply in 2021 and 2022.

VLA2001 is produced using Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO^®. Valneva has commenced production in parallel to the ongoing clinical development in order to prepare for deliveries of VLA2001 following approval, if received.

CHIKUNGUNYA VACCINE CANDIDATE – VLA1553
Pivotal Phase 3 clinical trial initiated

VLA1553 is a vaccine candidate against the chikungunya virus, a mosquito-borne virus that has spread to more than 100 countries with the potential to rapidly expand further. There are currently no preventive vaccines or effective treatments for the chikungunya virus available and, to Valneva’s knowledge, VLA1553 is the only chikungunya vaccine candidate in Phase 3 clinical trials worldwide.

VLA1553 is a live-attenuated, single dose vaccine candidate for protection against chikungunya disease. VLA1553 has been designed by deleting a part of the chikungunya virus genome. As a live-attenuated vaccine, VLA1553 is particularly well suited to target long-lasting protection which differentiates it when compared to other chikungunya assets that are being evaluated in clinical trials.

The pivotal Phase 3 trial, VLA1553-301, was initiated in September 2020. The primary objective of the trial is to evaluate the immunogenicity and safety of VLA1553 at 28 days following a single immunization. A total of 4,131 adults aged 18 or above have been recruited across 44 sites in the United States⁷. Valneva has also initiated a clinical lot-to-lot consistency trial to show manufacturing consistency of the vaccine and an antibody persistence trial that will follow the immunogenicity subset for a period of up to five years.

The FDA has confirmed that Valneva can seek licensure through the FDA’s accelerated approval pathway. Therefore, the Company plans to seek licensure of the vaccine based on a surrogate of protection that is expected to reasonably predict protection from chikungunya infection.

VLA1553 received Fast Track designation from the FDA and PRIME designation from the European Medicines Agency. The sponsor of the first chikungunya vaccine Biologics License Application to be approved in the United States may be eligible to receive a Priority Review Voucher.

To make VLA1553 accessible to Low and Middle Income Countries (LMIC), Valneva and the Butantan Institute in Brazil entered into a collaboration agreement in January 2021 for the development, manufacturing and marketing of VLA1553⁸. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019⁹.

First Quarter 2021 Financial Review
(Unaudited, consolidated under IFRS)

Revenues
Valneva’s total revenues were €23.2 million in the first quarter of 2021 compared to €35.2 million in the first quarter of 2020.

Product sales declined by 50.7% to €16.1 million in the first quarter of 2021 compared to €32.7 million in the first quarter of 2020. On a CER basis¹⁰, product sales declined by 47.8% in the first quarter of 2021 compared to the first quarter of 2020 due to the COVID-19 pandemic impact on the travel industry. IXIARO^®/JESPECT^® sales declined by 41.8% (37.2% at CER) to
€13.3 million and DUKORAL^® sales by 98.9% (98.8% at CER) to €0.1 million in the first quarter of 2021 compared to €22.9 million and €9.7 million respectively in the first quarter of 2020. Third Party product sales grew to €2.7 million in the first quarter of 2021 from €0.1 million in the first quarter of 2020. The increase in Third Party product sales was driven by incremental sales related to Valneva’s distribution agreement with Bavarian Nordic for the sales of Rabipur/RabAvert and Encepur in certain territories that commenced in 2021.

Other Revenues, including revenues from collaborations, licensing and services, amounted to €7.1 million in the first quarter of 2021 compared to €2.5 million in the first quarter of 2020. This increase is primarily attributable to the €2.6 million of revenues related to the Lyme R&D collaboration agreement with Pfizer which was the main driver for the increase in collaboration and licensing revenues.

Operating result and EBITDA
Costs of goods and services sold (COGS) were €14.6 million in the first quarter of 2021. Gross margin on product sales was 41.7% compared to 67.3% in the first quarter of 2020. The decline was mainly related to idle capacity costs combined with compressed product sales, both impacting gross margin as a percentage of sales. COGS of €5.9 million were related to IXIARO^®/JESPECT^® sales, yielding a product gross margin of 55.9%. COGS of €1.7 million were related to DUKORAL^® sales, causing a negative product gross margin. Of the remaining COGS in the first quarter of 2021, €1.9 million were related to the Third Party Product distribution business and €5.1 million were related to cost of services. In the first quarter of 2020, overall COGS were €12.8 million, of which €10.7 million related to cost of goods and €2.1 million related to cost of services.

Research and development investments continued to increase as planned in the first quarter of 2021, growing to €27.7 million compared to €13.3 million in the first quarter of 2020. This was mainly driven by investments in Valneva’s COVID-19 vaccine VLA2001 as well as Phase 3 clinical study costs for Valneva’s chikungunya vaccine program VLA1553. Excluding COVID-19, research and development investments amounted to €12.1 million in the first quarter of 2021 compared to €13.1 million in the first quarter of 2020. Marketing and distribution expenses in the first quarter of 2021 amounted to €4.9 million compared to €6.0 million in the first quarter of 2020. The decrease was the result of lower marketing and distribution spend across all Valneva’s direct markets due to reduced sales activity as a result of the COVID-19 pandemic. Marketing and distribution expenses in the first quarter of 2021 notably included €1.2 million of expenses related to the launch preparation costs of the chikungunya vaccine candidate (compared to none in the first quarter of 2020). In the first quarter of 2021, general and administrative expenses increased to €10.0 million from €5.2 million in the first quarter of 2020, mainly driven by increased costs to support corporate transactions and projects.

Other income, net of other expenses, increased to €3.0 million in the first quarter of 2021 from €2.2 million in the first quarter of 2020. This increase was mainly driven by increased R&D tax credits directly resulting from increased R&D spending.

Valneva recorded an operating loss of €31.1 million in the first quarter of 2021 compared to an operating profit of €0.1 million in the first quarter of 2020. EBITDA loss in the first quarter of 2021 was €28.3 million compared to an EBITDA profit of €2.4 million in the first quarter of 2020.

Net result
In the first quarter of 2021, Valneva generated a net loss amounting to €27.7 million compared to a net loss of €1.2 million in the first quarter of 2020.

Finance costs and currency effects in the first quarter of 2021 resulted in a net finance income of €3.1 million, compared to a net finance expense of €2.2 million in the first quarter of 2020. This was mainly a result of foreign exchange gains amounting to €7.7 million in the first quarter of 2021 primarily driven by revaluation gains of non-Euro denominated balance sheet positions compared to a net foreign exchange loss of €1.0 million in the first quarter of 2020. Interest charges increased to €4.6 million in the first quarter of 2021 compared to €1.3 million in the same period of 2020. This growth was driven by increased interest charges related to the financing agreement with US healthcare funds Deerfield & Orbimed entered into in 2020 as well as interest charges related to refund liabilities.

Cash flow and liquidity
Net cash generated by operating activities amounted to €47.6 million in the first quarter of 2021 compared to €3.0 million in the first quarter of 2020 mainly driven by milestone payments related to the COVID supply agreement concluded with the UK Government in September 2020.

Cash outflows from investing activities amounted to €16.9 million in the first quarter of 2021 compared to €0.6 million in the first quarter of 2020 mainly as a result of purchases of equipment related to the site expansion activities related to COVID manufacturing in both Scotland and Sweden.

Cash outflows from financing activities amounted to €1.6 million in the first quarter of 2021 and consisted of €3.4 million of interest payments as well as €2.2 million of cash proceeds related to issuance of new shares related to employee stock option programs. Cash inflows in the first quarter of 2020 amounted to €14.5 million and consisted of net proceeds from the financing arrangement with US healthcare funds Deerfield and OrbiMed, offset by €20.0 million of repayments of borrowings to the European Investment Bank (EIB).

Liquid funds increased to €235.9 million as of March 31, 2021 compared to €204.4 million as of December 31, 2020. The main changes related to payments made by the UK Government within the framework of the UK COVID-19 partnership.

About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine Director Investor Relations & Corporate Communications M +33 (0)6 4516 7099 investors@valneva.com

Teresa Pinzolits Corporate Communications Specialist T +43 (0)1 20620 1116 communications@valneva.com

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to expected total revenues and R&D expenses for full fiscal year 2021, the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates and estimates for future performance. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of future performance. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-IFRS Financial Measures

Management uses and presents IFRS results as well as the non-IFRS measure of EBITDA to evaluate and communicate its performance. While non-IFRS measures should not be construed as alternatives to IFRS measures, management believes non-IFRS measures are useful as an aid to further understand Valneva’s current performance, performance trends, and financial condition.

EBITDA is a common supplemental measure of performance used by investors and financial analysts. Management believes this measure provide additional analytical tools. EBITDA is defined as earnings (loss) from continuing operations before interest expense, income taxes, depreciation and amortization.

A reconciliation of EBITDA to operating profit (loss), the most directly comparable IFRS measure, is set forth below:

€ in million	3 months ending March 31
	2021	2020
Operating (loss)/Profit	(31.1)	0.1
Add:
Amortization	1.5	1.5
Depreciation	1.3	0.8
EBITDA	(28.3)	2.4

---

1 EBITDA is a non-IFRS financial measure. See “Non-IFRS Financial Measures” section included herein for more information regarding our use of EBITDA and a reconciliation to operating profit (loss), the most directly comparable financial measures calculated in accordance with IFRS.
2 Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium.
3 Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
4 Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate
5 Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
6 Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program
7 Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial
8 Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries
9 CEPI awards up to $23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine
10 CER: Constant Exchange Rate; First quarter 2020 actuals restated to first quarter 2021 average exchange rates

Exhibit 99.3

 

Valneva Reports Q1 2021 Financial Results and Business Update Analyst Presentation May 20, 2021

Disclaimer Valneva Q1 2021 Analyst Presentation May 20, 2021 2 This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful . The Valneva shares may not be offered or sold in the USA . The offer and sale of the Valneva shares has not been registered under the 1933 US Securities Act, as amended . Valneva is a European company . Information distributed is subject to European disclosure requirements that are different from those of the United States . Financial statements and information may be prepared according to accounting standards which may not be comparable to those used generally by companies in the United States . This presentation includes only summary information and does not purport to be comprehensive . Any information in this presentation is purely indicative and subject to modification at any time . Valneva does not warrant the completeness, accuracy or correctness of the information or opinions contained in this presentation . None of Valneva, or any of their affiliates, directors, officers, advisors and employees shall bear any liability for any loss arising from any use of this presentation . Certain information and statements included in this presentation are not historical facts but are forward - looking statements, including statements with respect to revenue guidance, the progress, timing and completion of research, development and clinical trials for product candidates and estimates for future performance . The forward - looking statements (a) are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Valneva operates, and involve known and unknown risk, uncertainties and other factors, which may cause actual results, performance or achievements to be materially different from those expressed or implied by these forward - looking statements, (b) speak only as of the date this presentation is released, and (c) are for illustrative purposes only . Investors are cautioned that forward - looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Valneva . Non - IFRS Financial Measures Management uses and presents IFRS results as well as the non - IFRS measure of EBITDA to evaluate and communicate its performance . While non - IFRS measures should not be construed as alternatives to IFRS measures, management believes non - IFRS measures are useful as an aid to further understand Valneva's current performance, performance trends, and financial condition . EBITDA is a common supplemental measure of performance used by investors and financial analysts . Management believes this measure provide additional analytical tools . EBITDA is defined as earnings (loss) from continuing operations before interest expense, income taxes, depreciation and amortization . A reconciliation of EBITDA to operating profit (loss), the most directly comparable IFRS measure, is set forth in this presentation .

Agen d a Valneva Q1 2021 Analyst Presentation May 20, 2021 3 Introduction Business Update Financial Report Q1 2021 Newsflow Q&A

Valneva Reports Q1 2021 Financial Results and Business Update ▪ Excellent progress on clinical programs ▪ Initiation of additional Phase 2 trial to accelerate pediatric development for Lyme vaccine ▪ Initiation of pivotal Phase 3 clinical trial for COVID - 19 vaccine; participation in COVID - 19 vaccine booster trial ▪ Chikungunya pivotal Phase 3 trial recruitment completion ▪ Successful Nasdaq listing (Q2); $107.6 million of gross proceeds ▪ Cash / cash equivalents of €235.9 million at end of March (excluding proceeds from Global Offering) ▪ Q1 2021 total revenue of €23.2 million compared to €35.2 million in Q1 2020 Valneva Q1 2021 Analyst Presentation May 20, 2021 4

Agen d a Valneva Q1 2021 Analyst Presentation May 20, 2021 5 Introduction Business Update Financial Report Q1 2021 Newsflow Q&A

FDA Fast Track Designation granted Multivalent vaccine (six serotypes) to protect against Lyme disease in the United States and Europe Follows proven Mechanism of Action for a Lyme disease vaccine Initial results reported from Phase 2 trials 1, 2 Accelerated pediatric trial (VLA15 - 221) initiated in March 2021 3 VLA15 – Multivalent Lyme Disease Vaccine Candidate Only Program in Advanced Clinical Development Today 1 2 4 5 Exclusive, worldwide partnership with Pfizer 3 Valneva Q1 2021 Analyst Presentation May 20, 2021 6 1 Valneva announces positive initial results for Phase 2 study of Lyme Disease vaccine candidate. 2 Valneva announces positive initial results for second Phase 2 study of Lyme Disease vaccine candidate VLA15. 3 Valneva announces acceleration of pediatric development for Lyme Disease vaccine candidate.

VLA15: Development Outlook Valneva Q1 2021 Analyst Presentation May 20, 2021 7 Phase 2 trial (VLA15 - 221) in adults and pediatric subjects initiated 1 ▪ Trial to include participants from 5 - 65 years of age and a reduced immunization schedule (Month 0 - 6 compared to Month 0 - 2 - 6) ▪ The trial triggered a milestone payment of $10 million, upon dosing of the first subject, from Pfizer to Valneva ▪ Initial pediatric population data expected in Q2 2022 1 ▪ VLA15 - 221 will also investigate a booster dose of VLA15, administered one year following the six Month dose 1 Phase 3 pivotal efficacy trial planned to commence pending positive readout from VA15 - 221 in 2022 1 ▪ Clinical readout, based on one tick season, projected end 2023 First licensure anticipated H1 2025, subject to regulatory approval 1 Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate.

UK government deal worth up to €1.4 billion 1 with development and manufacturing funding; ongoing dialogue with other potential customers Program acceleration enabled through use of Valneva’s FDA - registered facility in UK; commercial manufacturing commenced January 2021 3 2 Phase 1/2 clinical trial results reported 5 , Phase 3 ongoing 4 Regulatory submission to MHRA planned in autumn 2021, deliveries thereafter, subject to approval 5 Combines Valneva’s proven approach of inactivated vaccines with Dynavax’s advanced CpG 1018 adjuvant 4 3 VLA2001 – The Only Inactivated Vaccine in Clinical Development in Europe : Adjuvanted with CpG1018 Note: Photo credit: CDC/Alissa Eckert, MSMI; Dan Higgins, MAM. 1 Valneva announces major COVID - 19 vaccine partnership with U.K. Government . 2 Valneva in advanced discussion with European Commission to supply up to 60m doses of Inactivated, Adjuvanted COVID - 19 vaccine candidate . 3 Valneva commences manufacturing of its Inactivated, Adjuvanted COVID - 19 vaccine, completes Phase 1/2 study recruitment . 4 Valneva and Dynavax announce commercial supply agreement for Inactivated, Adjuvanted COVID - 19 vaccine . 5 Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID - 19 Vaccine Candidate, VLA2001 1 Valneva Q1 2021 Analyst Presentation May 20, 2021 8

VLA2001 Was Well Tolerated in Phase 1/2 Safety Profile Within the Expected Range for an Inactivated Vaccine ▪ Generally well tolerated across all dose groups tested, no sa f e t y con c erns ident i fied by an independent Data Safety Monitoring Board. ▪ N o statistic a l ly sig n ificant di f f erences be t w e e n dose groups and no differences between first and second vaccinations in terms of reactogenicity . ▪ Majority of Adverse Events (AEs) were mild or moderate and only two subjects reported severe solicited AEs (headache and fatigue) . ▪ All solicited AEs were transient . ▪ Only 17 . 6 % of unsolicited AEs up to day 36 were considered related to the vaccine and no severe un s olicited AEs w ere repo r ted . ▪ No serious related AEs . Safety Analysis Set, Figure 1.1.1 and 1.1.2, Table 14.2.1.2 and 14.2.1.3 29 . 4 30 . 6 28 . 0 5 . 9 2 . 0 0 . 0 49 . 0 32 . 7 44 . 0 3 . 9 0.0 0.0 3 . 9 6 . 1 2 . 0 35 . 3 22 . 4 30 . 0 33 . 3 18 . 4 30 . 0 19 . 6 12 . 2 20 . 0 0 1 0 2 0 3 0 4 0 5 0 Subjects with Solicited Symptoms (%) EVE N T S D ose Gr o u ps Lo w D o s e ( n = 51 ) M ediu m D o s e ( n = 49 ) H ig h D o s e ( n = 50 ) 27 .5 27 . 5 33 . 3 5 . 9 3 . 9 37 . 3 31 . 4 43 . 1 2.0 2.0 0.0 7 . 8 5.9 9 . 8 35 . 3 19 . 6 39 . 2 31 . 4 21 . 6 33 . 3 27 .5 27 . 5 23 . 5 0 1 0 2 0 3 0 4 0 S u b j ec t s w i t h S o l i c i t ed S y m p t o m s ( % ) EVE N T S H ig h D o s e ( n = 51 ) Medium Dose(n=51) Low Dose(n=51) D ose Gr o u ps Valneva Q1 2021 Analyst Presentation May 20, 2021 9 First v accin a tion Second v accin a tion

VLA2001 Was Highly Immunogenic in Phase 1/2 > 90% of Trial Participants Developed Significant Levels of Antibodies Per - Protocol Analysis Set, Table 14.3.5.1, Table 14.3.6.1 ▪ More than 90% of all trial participants developed significant levels of antibodies to the SARS - CoV - 2 virus spike protein across all dose groups tested. ▪ Seroconversion Rates (SCR) for S - protein binding IgG antibodies were 89.8% in the medium dose and 100% in the high dose group. ▪ Two weeks after completion of the two dose schedule, Geometric Mean Fold Rises (GMFRs) from baseline were 26 in the medium dose and 86 in the high dose group. Day 36 Proportion of Subjects with Seroconversion in Terms of S - protein specific IgG Antibodies (%) with 95% CI Seroconversion as Measured by IgG Against S - protein (ELISA) 100 90 80 70 60 50 40 30 20 10 0 Day 22 Low Dose Medium Dose Hi g h Do s e O v er a ll Valneva Q1 2021 Analyst Presentation May 20, 2021 10

VLA2001 Generated Neutralizing Antibody Titers at or Above Levels Generally Seen in Convalescent Sera in Phase 1/2 ▪ Dose dependent response, statistically significant higher Geometric Mean Titers (GMTs) in high dose group compared to low and medium dose groups. ▪ In high dose group, GMT of neutralizing antibody titers of 530.4 (95% CI: 421.49, 667.52). ▪ With a GMT ratio of vaccine vs. convalescent sera ≥ 1 vaccine efficacy has been reported above 80% for other vaccines. Conva l e sc en t Se ra 1000 0 2000 ) 0 5 1500 A N M 100 0 ( s e r t T 50 0 i y d o b i t n A 20 0 g n i z i l r 10 0 a t u e N 5 0 1 0 F i gu r e 1 . 2 . 2 Plot of SARS - CoV - 2 Neutralizing Antibodies (ND50) for Convalescent Sera A l l C on v a l e s c e nt S ub j e c t s (N = 32 ) P - value: <0.001 D a y 3 6 Figure 1.2.1 Plot of SARS - CoV - 2 Neutralizing Antibodies (ND50) Over Time by Dose Groups Per - Protocol Analysis Set (N=150) Day 1 Day 8 Day 22 P - value: 0.349 P - value: 0.129 P - value: 0.089 Low Medium High Low Medium High Low Medium High Low Medium High Dose groups Day1: Low(n=51) Medium(n=49) High(n=50); Day8: Low(n=51) Medium(n=49) High(n=50); Day22: Low(n=50) Medium(n=48) High(n=48); Day36: Low(n=51) Medium(n=48) High(n=50); Note: Graph shows GMT and 95% CI. Green scatter dots are the actual distribution of neutralizing antibody titres. Data Source: ADIS, Table 14.3.1.1 Program Location: E: \ Projects \ 1222Valneva \ Stats \ Programs \ F_1_2_1 Date: 01APR2021:00:49 1 0 10 0 5 0 20 0 50 0 200 0 150 0 100 0 1000 0 Valneva Q1 2021 Analyst Presentation May 20, 2021 11 Neutralizing Antibody Titres (MNA50) Per - Protocol Analysis Set, Figure 1.2.1; Convalescent Subjects, Figure 1.2.2 Earle et al. MedRxiv, March 2021, https://doi.org/10.1101/2021.03.17.20200246); Khoury et al. MedRxiv, March 2021, https://doi.org/10.1101/2021.03.09.21252641 SARS - CoV - 2 N e u traliz in g Antibodies (MNA50) Graph shows GMT and 95% CI. Green scatter dots are the actual distribution of neutralizing antibody titres. Source. ADIS, Table 14.5.1.1

Immunogenicity Summary – Cellular Response Induced Exploratory endpoints evaluated T - cell responses by IFNgamma ELISpot analysis against S - protein, M embrane - protein and N ucleocapsid - protein. At Day 36, in the high dose group: ▪ 76 % of study participants ( 34 / 45 ) were reactive 1 against peptide pools spanning the full - length S - protein ▪ 36% (16/45) against the M - protein ▪ 49% (22/45) against the N - protein S - protein Reactive Non - reactive M - protein Reactive Non - reactive N - protein Reactive Non - reactive 1 Sample is considered reactive against individual stimulation panel (peptide pools) if normalized spot counts (Nil control counts substracted) per 2.10 x 10^5 PBMCs ≥ 6 Valneva Q1 2021 Analyst Presentation May 20, 2021 12

Pivotal Phase 3 is a randomized, observer - blind, controlled, comparative immunogenicity trial in ~ 4,000 adults ▪ Immunological comparison against a licensed vaccine to reasonably predict efficacy (superiority of VLA2001 in a two - dose immunization schedule four weeks apart - GMTs of neutralising antibodies, at two weeks after the second vaccination) ▪ Study conducted in UK supported by DHSC/NIHR, including funding ▪ Protocol agreed with MHRA; discussion with other regulatory bodies ongoing Valneva participates in the world’s first COVID - 19 vaccine booster trial in the UK Additional booster studies planned (including reduced booster dose) Valneva has developed viral seed banks, including South African and Kent, to be in a position to manufacture variant - based vaccines Valneva Q1 2021 Analyst Presentation May 20, 2021 13 VLA2001: Development Outlook Pivotal Phase 3 Trial Ongoing

VLA1553 – Only Chikungunya Vaccine Candidate in Phase 3 Today Note : Photo credit : James Gathany . 1 Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Tria l 2 Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates 3 Valneva reports positive End - of - Phase 2 Chikungunya meeting with the U . S . FDA and sets stage for Phase 3 Study ; 4 https : //www . fda . gov/about - fda/center - drug - evaluation - and - research - cder/tropical - disease - priority - review - voucher - program . 5 Valneva awarded FDA Fast Track Designation for Chikungunya vaccine candidate . 6 Valneva’s Chikungunya vaccine candidate awarded EMA prime designation . 7 CHIKV LR 2006 - OPY 1 infectious clone was attenuated by deleting large part of gene coding nsP 3 (alphavirus - replicase) . 8 Valneva to partner with Instituto Butantan on single - shot Chikungunya vaccine for low - and middle - Income countries . Phase 3 trial VLA1553 - 301 fully enrolled 1 ; Use of surrogate marker for Ph3 endpoint confirmed by FDA 2 ; Accelerated Approval Pathway confirmed 3 Potentially eligible for Priority Review Voucher 4 ; FDA Fast Track 5 and EMA PRIME 6 designation granted Single shot, live attenuated 7 prophylactic vaccine targeting chikungunya virus neutralization Up to $23.4 million awarded to Valneva for R&D by CEPI; Partnership with Instituto Butantan for LMICs 8 Excellent fit with existing commercial and manufacturing capabilities 1 2 4 5 3 Valneva Q1 2021 Analyst Presentation May 20, 2021 14

VLA1553: Development Outlook Pivotal Phase 3 Trial - Topline Read - out Expected Mid - 2021 1 Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial 2 Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single - Shot Chikungunya Vaccine Candidate . 3 In collaboration with development partner Instituto Butantan, under CEPI funding. 4 Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates 5 https://www.fda.gov/about - fda/center - drug - evaluation - and - research - cder/tropical - disease - priority - review - voucher - program . Valneva Q1 2021 Analyst Presentation May 20, 2021 15 Phase 3 Clinical Development Program underway ▪ Pivotal Phase 3 safety and immunogenicity trial in 4,131 healthy volunteers fully enrolled 1 ▪ Topline read - out on Day 29 (based on surrogate of protection) mid - 2021 ▪ Lot - to - Lot consistency trial initiated (VLA1553 - 302) in ~400 volunteers 2 ▪ Antibody persistence follow - up trial initiated (VLA1553 - 303) – up to 375 volunteers from VLA1553 - 301 will be followed up annually for five years after a single immunization 1 ▪ Adolescents’ clinical trial in 750 volunteers in Brazil planned to commence in 2021 3 ▪ Accelerated approval pathway agreed with FDA 4 VLA1553 may be eligible for Priority Review Voucher upon FDA approval 5

Agen d a Valneva Q1 2021 Analyst Presentation May 20, 2021 16 Introduction Business Update Financial Report Q1 2021 Newsflow Q&A

Strong Cash Position of €235.9 million at End of March to be Complemented by Proceeds from Global Offering Cash and cash equivalents of €235.9 million at March 31, 2021 ▪ The increase in liquid funds compared to December 31, 2020 results from payments made by the UK Government within the framework of the UK COVID - 19 partnership. Successful Nasdaq listing in May 2021 ▪ $107.6 million of gross proceeds raised in a US initial public offering and a concurrent private placement in Europe. Valneva Q1 2021 Analyst Presentation May 20, 2021 17

Results Dynamics and Out look Valneva Q1 2021 Analyst Presentation May 20, 2021 18 Total revenues, excluding VLA2001, expected in range of €80 million to €105 million Revenue guidance, excluding COVID - 19, updated taking into account ongoing impacts of COVID - 19 on travel industry ▪ Variants causing havoc in some key destinations (e.g. India) ▪ Ongoing pandemic setting in others such as Brazil ▪ Inconsistent vaccine program roll out in some key markets (e.g. Canada) COVID - 19 revenue guidance to be provided in due course but still early days ▪ Ongoing Phase 3 and regulatory discussions outside the UK ▪ Role of VLA2001 as a booster ▪ Potential switch to variant ▪ Ongoing discussions with EC

IXIARO ® US Military €12.3m TPP 1 €2.7m IXI A R O ® JESPE CT ® Travel €1.0m Q1 2021 Sales Adversely Affected by the COVID - 19 Pandemic Q1 2021 Product Sales (unaudited) Direct sales 98% Gross margin³ 41.7 % Product sales² - 51% AE R / - 48% CER AER: Actual exchange rates, CER: Constant exchange rates; 1 Third party products sold by Valneva‘s commercial organization, 2 YoY comparison for same period, 3 Gross margin on product sales Net product sales €16.1m Valneva Q1 2021 Analyst Presentation May 20, 2021 19 DUKORAL ® €0.1m

EBITDA Loss Reflecting Increasing R&D Expenses / Lower Sales Q1 2021 Profit & Loss Report (unaudited) Valneva Q1 2021 Analyst Presentation May 20, 2021 20 1 EBITDA is a non - IFRS financial measure. A reconciliation to operating profit (loss), the most directly comparable financial measures calculated in accordance with IFRS, is included herein. Q1 2021 EBITDA was calculated by excluding €2.8 million (Q1 2020: €2.3 million) of depreciation and amortization from the €31.1 million operating loss (Q1 2020: €0.1 million operating profit) as recorded in the consolidated income statement under IFRS. €m Q1 2021 Q1 2020 Product sales 16.1 32.7 Revenues from collaboration, licensing and services 7.1 2.5 Revenues 23.2 35.2 Cost of goods (9.6) (10.7) Cost of services (5.1) (2.1) Research and development expenses (27.7) (13.3) Marketing and distribution expenses (4.9) (6.0) General and administrative expenses (10.0) (5.2) Other income / (expense), net 3.0 2.2 Operating profit / (loss) (31.1) 0.1 Finance, investment in associates & income taxes 3.4 (1.3) Loss for the period (27.7) (1.2) EBITDA 1 (28.3) 2.4

Effect of SARS - CoV - 2 program on Group P&L COVID - 19 Program Reported as Separate Segment as of 2021 Valneva Q1 2021 Analyst Presentation May 20, 2021 21 1 EBITDA is a non - IFRS financial measure. A reconciliation to operating profit (loss), the most directly comparable financial measures calculated in accordance with IFRS, is included herein. Q1 2021 EBITDA was calculated by excluding €2.8 million of depreciation, amortization and impairment from the €31.1 million operating loss as recorded in the consolidated financial statements under IFRS. €m Q1 2021 Group Q1 2021 COVID only Q1 2021 excl. COVID Product sales 16.1 16.1 Revenues from collaboration, licensing and services 7.1 7.1 Revenues 23.2 23.2 Cost of goods (9.6) (0.2) (9.4) Cost of services (5.1) (5.1) Research and development expenses (27.7) (15.7) (12.1) Marketing and distribution expenses (4.9) (0.1) (4.8) General and administrative expenses (10.0) (5.4) (4.6) Other income / (expense), net 3.0 - 3.0 Operating profit / (loss) (31.1) (21.4) (9.8) Finance, investment in associates & income taxes 3.4 3.4 Loss for the period (27.7) (21.4) (6.4) EBITDA 1 (28.3) (20.3) (8.0)

Balance Sheet Statement Per March 31, 2021 – before US IPO effects on Cash & Equity Valneva Q1 2021 Analyst Presentation May 20, 2021 22 ASSETS Mar 31, 2021 Dec 31, 2020 NON - CURRENT ASSETS 157,132 140,737 + Intangible Assets 35,156 35,409 + Right Of Use Assets 42,592 43,374 + Property, plant & equipment 51,030 34,779 + Other non - current assets 28,353 27,176 CURRENT ASSETS 416,981 308,427 + Inventories 97,400 26,933 + Trade receivables 25,100 19,232 + Other current assets 58,568 57,828 + Cash & current financial assets 235,913 204,435 TOTAL ASSETS 574,112 449,164 EQUITY & LIABILITIES Mar 31, 2021 Dec 31, 2020 EQUITY 52,355 77,422 NON - CURRENT LIABILITIES 201,401 195,872 + Borrowings, long term 48,868 46,375 + Refund Liabilities 99,637 97,205 + Other long term liabilities, including Lease Liabilities 52,897 52,292 CURRENT LIABILITIES 320,357 175,870 + Trade payables and accruals 60,878 36,212 + Borrowings, short term 5,944 6,988 + Contract Liabilities 204,956 89,578 + Refund Liabilities 18,818 14,222 + Other current liabilities, including Lease Liabilities 29,760 28,871 TOTAL EQUITY AND LIABILITIES 574,112 449,164

Agen d a Valneva Q1 2021 Analyst Presentation May 20, 2021 23 Introduction Business Update Financial Report Q1 2021 Newsflow Q&A

Key Upcoming Catalysts and Potential Inflection Points Valneva Q1 2021 Analyst Presentation May 20, 2021 24 Lyme disease vaccine candidate VLA15 ▪ Further Phase 2 milestones and read - outs during 2021; Phase 2 study VLA15 - 221, including pediatric development, initiated March 2021 Chikungunya vaccine candidate VLA1553 ▪ Initial Phase 3 data expected mid - 2021; Phase 3 now fully recruited COVID - 19 vaccine candidate VLA2001 ▪ Phase 1/2 initial data reported, Phase 3 data expected in Q3 2021 ▪ Regulatory submissions planned autumn 2021 assuming clinical data positive ▪ Further trial initiations to strengthen the product candidate’s differentiation ▪ Further supply deals subject to negotiations and capacity

Supplemental Disclosures Regarding Non - IFRS Financial Measures Valneva Q1 2021 Analyst Presentation May 20, 2021 25 EBITDA is a common supplemental measure of performance used by investors and financial analysts. Management believes this measure provide additional analytical tools. EBITDA is defined as earnings (loss) from continuing operations before interest expense, income taxes, depreciation and amortization. A reconciliation of EBITDA to operating profit (loss), the most directly comparable IFRS measure, is set forth below: € in million 3 months ending March 31 2021 2020 Operating (loss)/Profit (31.1) 0.1 Add: Amortization 1.5 1.5 Depreciation 1.3 0.8 EBITDA (28.3) 2.4

Agen d a Valneva Q1 2021 Analyst Presentation May 20, 2021 26 Introduction Business Update Financial Report Q1 2021 Newsflow Q&A

Thank you Merci Danke Tack